Literature DB >> 2379029

The booster injection of antigen during active sensitization of guinea-pig modifies the anti-anaphylactic activity of the PAF antagonist WEB 2086.

S Desquand1, J Lefort, C Dumarey, B B Vargaftig.   

Abstract

1. Serum IgG levels of sensitized guinea-pigs bled at various times after the booster injection were evaluated and its capacity to sensitize passively lung strips from normal guinea-pigs assessed. Following the booster injection, both serum IgG and the ability to sensitize passively lung strips increased during the first week and decreased slowly thereafter. 2. The PAF antagonist WEB 2086 (3 mg kg-1, i.v.) blocked the anaphylactic bronchoconstriction induced by intravenous administration of ovalbumin (1 mg kg-1) when guinea-pigs were challenged 2 and 4 days after the booster injection, but became ineffective when tested in guinea-pigs challenged 7, 28 and 56 days after the booster injection. 3. The ability of WEB 2086 to reduce anaphylactic bronchoconstriction of guinea-pigs challenged 2 and 4 days after the booster injection was unrelated to either the selective involvement of one type of immunoglobulin, low IgG titres in sera or a reduced sensitizing capacity. 4. The booster injection, which accounts for the loss of efficacy of WEB 2086 from the fourth day thereafter, probably operates as a PAF-independent inflammatory challenge. 5. The protocol for immunisation and the day of experiment after the booster injection determines the sensitivity of the anaphylactic bronchoconstriction to inhibition of PAF antagonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379029      PMCID: PMC1917441          DOI: 10.1111/j.1476-5381.1990.tb15785.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock.

Authors:  W E BROCKLEHURST
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

2.  Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis.

Authors:  J Casals-Stenzel
Journal:  Immunopharmacology       Date:  1987-04

3.  A high-sampling-rate automated continuous-flow fluorometric technique for the analysis of nanogram levels of histamine in biological samples.

Authors:  B Lebel
Journal:  Anal Biochem       Date:  1983-08       Impact factor: 3.365

4.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.

Authors:  B B Vargaftig; J Lefort; M Chignard; J Benveniste
Journal:  Eur J Pharmacol       Date:  1980-07-25       Impact factor: 4.432

5.  Analytical methods for thromboxane B2 measurement and validation of radioimmunoassay by gas liquid chromatography-mass spectrometry.

Authors:  H Sors; P Pradelles; F Dray; M Rigaud; J Maclouf; P Bernard
Journal:  Prostaglandins       Date:  1978-08

6.  Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs. Pattern of response in relation to immunization regimen.

Authors:  P Andersson
Journal:  Allergy       Date:  1980-01       Impact factor: 13.146

7.  The cat lung strip as an in vitro preparation of peripheral airways: a comparison of beta-adrenoceptor agonists, autacoids and anaphylactic challenge on the lung strip and trachea.

Authors:  K M Lulich; H W Mitchell; M P Sparrow
Journal:  Br J Pharmacol       Date:  1976-09       Impact factor: 8.739

8.  Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs. The effect of booster injection and cyclophosphamide treatment.

Authors:  P Andersson
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

9.  Effect of the PAF antagonists, CV-3988 and L-652,731 on the pulmonary and hematological responses to guinea pig anaphylaxis.

Authors:  G Danko; J E Sherwood; B Grissom; W Kreutner; R W Chapman
Journal:  Pharmacol Res Commun       Date:  1988-09

10.  Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; interactions with salicylic acid.

Authors:  J Lefort; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1978-05       Impact factor: 8.739

View more
  9 in total

1.  Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect.

Authors:  N M Concessio; M M VanOort; M R Knowles; A J Hickey
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Induction by aerosol allergen of sustained and nonspecific IgE-mediated airway hyperreactivity in the guinea pig.

Authors:  D A Handley; J J DeLeo; A M Havill
Journal:  Agents Actions       Date:  1992-11

Review 3.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Multiple antigen challenge produces pulmonary eosinophilia but not pulmonary hyperresponsiveness in actively sensitized guinea pigs.

Authors:  J W Watson; V L Cohan; A K Shay; K W Freiert
Journal:  Agents Actions       Date:  1992-11

5.  Lipopolysaccharide from Escherichia coli reduces antigen-induced bronchoconstriction in actively sensitized guinea pigs.

Authors:  E Vannier; J Lefort; A Lellouch-Tubiana; B Terlain; B B Vargaftig
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

6.  Drug modulation of antigen-induced paw oedema in guinea-pigs: effects of lipopolysaccharide, tumour necrosis factor and leucocyte depletion.

Authors:  J I da Motta; F Q Cunha; B B Vargaftig; S H Ferreira
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Interference of BN 52021, an antagonist of PAF, with different forms of active anaphylaxis in the guinea-pig: importance of the booster injection.

Authors:  S Desquand; J Lefort; C Dumarey; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

8.  Effect of the hetrazepinoic platelet-activating factor antagonist Bepafant (WEB 2170) in models of active and passive anaphylaxis in mice and guinea pigs.

Authors:  H O Heuer
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

9.  Is platelet activating factor (PAF) an important mediator in bronchial asthma?

Authors:  R H Gundel; H O Heuer; L G Letts
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.